An Efficacy and Safety Study for JNS001 in Adults With Attention-Deficit Hyperactivity Disorder
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the efficacy of JNS001 titrated to daily doses
of 18 to 72 mg in adults with attention-deficit hyperactivity disorder (ADHD) relative to
placebo.